Additive manufacturing MicroFactory for amorphous solid dispersion formulations

Tools

Prasad, Elke and Robertson, John and Halbert, Gavin (2024) Additive manufacturing MicroFactory for amorphous solid dispersion formulations. In: CMAC Showcase 2024, 2024-09-16 - 2024-09-16, TIC.

[thumbnail of Prasad-etal-ElPr_Showcase2024_Additive_manufacturing_MicroFactory_for_amorphous_solid_dispersion_formulations]
Preview
 Text. Filename: Prasad-etal-ElPr_Showcase2024_Additive_manufacturing_MicroFactory_for_amorphous_solid_dispersion_formulations.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial 4.0 logo
Download (1MB)| Preview

Abstract

This study utilised the HUB Additive-Manufacturing-MicroFactory as an enabler for the streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® and Plasdone S-630 Ultra as a superior polymers to form stable ASD formulation with Ritonavir. The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® and Plasdone S-630 Ultra were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).

ORCID iDs

Prasad, Elke ORCID logoORCID: https://orcid.org/0000-0002-5412-9374, Robertson, John ORCID logoORCID: https://orcid.org/0000-0002-2191-1319 and Halbert, Gavin;
CORE (COnnecting REpositories)